Question 1

What is the catalog number for Firuglipel?

Accepted Answer

The catalog number for Firuglipel is M11532.

Question 2

What sizes are available for Firuglipel?

Accepted Answer

Firuglipel is available in the following size(s): 1 g, 200 mg, 500 mg, 5 mg, 50 mg, 100 mg.

Question 3

How many pack sizes does Firuglipel come in?

Accepted Answer

Firuglipel is available in 6 different pack sizes.

Question 4

Is Firuglipel in stock?

Accepted Answer

Firuglipel is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is Firuglipel used for?

Accepted Answer

Firuglipel (DS-8500, DS8500a) is a novel potent, selective, orally available GPR119 agonist with EC50 of 51.5 nM in human GPR119-expressing CHO-K1 cells.

Question 6

Is this kit compatible with automated liquid handling platforms?

Accepted Answer

Automation compatibility varies by kit and isn’t always listed on the datasheet. Contact our technical support team with details of your platform so we can confirm with the manufacturer.

Question 7

What applications has this product been validated for?

Accepted Answer

Validated applications such as WB, ELISA, IHC, ICC, or FC are listed on the product datasheet. If you need application-specific validation data before ordering, contact our technical support team with the catalogue number.

Question 8

How do I reconstitute this lyophilized product?

Accepted Answer

Reconstitution instructions, including the recommended diluent and final concentration, are provided on the datasheet. Aliquot immediately after reconstitution to avoid repeated freeze-thaw cycles.

Firuglipel

Product Specifications

CAS Number

Stability

Purity

Weight

Molecular Formula

Notes

Receptor

Available Sizes

Frequently Asked Questions

Explore Other Products

Serum amyloid A2 Rabbit Polyclonal Antibody (FITC)

SNIP1 Antibody

ERAL1 Antibody (FITC)

ERAL1 Antibody (FITC)

Recombinant Human E3 ubiquitin-protein ligase XIAP (XIAP)

Recombinant Human E3 ubiquitin-protein ligase XIAP (XIAP)